NCT05558943Not yet recruiting
Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital
Source: ClinicalTrials.gov · Last updated 2 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
AML in adults represents a group of heterogeneous diseases; the prognosis remains poor despite significant therapeutic advances in recent years. In order to optimize patient care, it is necessary to have "real life" data that exhaustively reports on the patients treated in our department. The objective of this study is: * To describe the AML treated within the hematology department * To optimize the management of patients with AML.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 750 (estimated)
- First submitted
- 10 Jun 2022
- Start date
- Oct 2025
- Primary completion date
- Jun 2030
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT05558943
What you commit to
- Study type: Observational
- Planned participants: 750
- From Oct 2025 to the primary completion date, Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Minor patients
- Acute promyelocytic leukemia (AML3)
Who the study is looking for
- Age :18 years and older
- Patients with AML
- Non objection to research
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Hematology, Hospital Saint Antoine Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.